AIM VACCINE (06660) announced its interim financial results, reporting revenue of 351 million yuan. It will continue to accelerate the commercialization and market preparation of its key products, including the iterative rabies vaccine series.

AIM VACCINE (06660) released its interim results for the six months ending June 30, 2026, reporting revenue of 351 million yuan; the loss attributable to shareholders of the parent company was 123 million yuan, with a loss per share of 0.1 yuan. In 2025, the company successfully entered the African market with its quadrivalent meningococcal polysaccharide vaccine, while the rabies vaccine made its debut in the Central American market, and the hepatitis B vaccine also achieved its first export. In terms of registration progress, six new registration projects were launched in the first half of 2026, involving hepatitis B, hepatitis A, and meningococcal vaccines in three countries across Southeast Asia, South Asia, and Africa. The registration process for the hepatitis B vaccine is actively underway in Southeast Asia, promising a new option for local hepatitis B prevention. The registration work for the hepatitis A vaccine in South Asia is proceeding orderly, aiming to enhance local hepatitis A control capabilities. Meanwhile, the MPSV4 vaccine is steadily advancing toward registration in Central Asia, with local market launch expected next year. The company is making every effort to prepare for the international commercialization of the upcoming iterative pneumonia vaccine and serum-free iterative rabies vaccine. Exclusive agency agreements have been reached with several countries in West Asia and Southeast Asia, establishing a bridge for product entry into local markets. At the same time, AIM VACCINE has officially signed a Memorandum of Understanding (MOU) with Egypt for the iterative pneumonia vaccine, further expanding its market layout in the Middle East and North Africa (MENA) region, laying a solid foundation for future sales growth. These achievements demonstrate AIM VACCINE's strong market expansion capabilities and indicate its increasing significance in the global vaccine market. Among the products under research, the company is aligning its product pipeline with international market demands. According to the latest World Health Organization (WHO) vaccine pre-certification list (2024-2026), the company is rapidly advancing the research and development of its iterative pneumonia vaccine and quadrivalent combined meningococcal vaccine, both of which are classified as vaccines with high-priority certification. Additionally, the company is actively developing respiratory syncytial virus vaccines and shingles vaccines, which are also in high demand in international markets. The company is striving to promote the registration and sale of these products both domestically and internationally, aiming for their WHO pre-certification. In terms of sold products, the company's marketed hepatitis A vaccine, hepatitis B vaccine, and rabies vaccine are all products prioritized for certification by the World Health Organization and are well-received in international markets. We have gradually launched a series of temperature monitoring products for vaccines, ensuring vaccine safety and efficacy, covering freeze-dried human rabies vaccine (Vero cells), recombinant hepatitis B vaccine (Hansenula yeast), ACYW135 group meningococcal polysaccharide vaccine (MPSV4), and inactivated hepatitis A vaccine (human diploid cells), adapting to diverse customer needs by offering a variety of specifications and further enhancing vaccine temperature control and identification, thereby upgrading the vaccine quality management level and improving product market competitiveness. In terms of capacity construction, the GMP workshops for the company's iterative pneumonia series vaccines and iterative rabies series vaccines have been constructed in phases and meet international standards. The III phase clinical samples and process verification samples of the serum-free iterative rabies vaccine, high-titer human diploid rabies vaccine, 23-valent pneumococcal polysaccharide vaccine, and 13-valent pneumococcal conjugate vaccine are all produced in the aforementioned workshops, fully preparing for rapid international market launch after these products hit the shelves. In the second half of 2026, AIM VACCINE will continue to accelerate the commercialization and market warming-up of key products such as the iterative rabies series vaccines, deepening cooperative ties with countries along the "Belt and Road" initiative, allowing more quality vaccines to benefit the unmet medical needs globally. We will leverage our self-developed mRNA technology platform as the engine to break through R&D barriers for urgent international vaccines like respiratory syncytial virus and shingles, while establishing a robust global competitiveness in quality and supply with automated production capabilities and a comprehensive temperature control system, committed to achieving the mission of manufacturing trustworthy vaccines and ensuring the health of the world's population.